title: Effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation.
abstract: Cholecystokinin, like many peptide hormones, is present as multiple molecular forms. CCK-58 has been identified as the dominant form in the circulation, whereas most of the studies of CCK-receptor interactions have been performed with CCK-8. Despite both sharing the pharmacophoric region of CCK, representing its carboxy terminal heptapeptide amide, studies in vivo have demonstrated biological diversity of action of the two peptides, with CCK-58, but not CCK-8, stimulating pancreatic fluid secretion and lengthening the interval between meals. Here, we have directly studied the ability of these two CCK peptides to bind to the type 1 CCK receptor and to stimulate it to elicit an intracellular calcium response. The calcium response relative to receptor occupation was identical for CCK-58 and CCK-8, with the longer peptide binding with approximately fivefold lower affinity. We also examined the ability of the two peptides to elicit receptor internalization using morphological techniques and to disrupt the constitutive oligomerization of the CCK receptor using receptor bioluminescence resonance energy transfer. Here, both full agonist peptides had similar effects on these regulatory processes. These data suggest that both molecular forms of CCK act at the CCK1 receptor quite similarly and elicit similar regulatory processes for that receptor, suggesting that the differences in biological activity observed in vivo most likely reflect differences in the clearance and/or metabolism of these long and short forms of CCK peptides.
authors.affiliation: Mayo Clinic, Department of Molecular Pharmacology and Experimental Therapeutics, 13400 East Shea Blvd., Scottsdale, AZ 85259, USA.
authors.forename: S Vincent
authors.initials: SV
authors.lastname: Wu
authors.forename: Kaleeckal G
authors.initials: KG
authors.lastname: Harikumar
authors.forename: Rebecca J
authors.initials: RJ
authors.lastname: Burgess
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Reeve
authors.forename: Laurence J
authors.initials: LJ
authors.lastname: Miller
mesh_terms: D000818:Animals; D016466:CHO Cells; D019556:COS Cells; D020013:Calcium Signaling; D002522:Chlorocebus aethiops; D002766:Cholecystokinin / Q000378:metabolism*; D006224:Cricetinae; D003412:Cricetulus; D004705:Endocytosis; D031541:Fluorescence Resonance Energy Transfer; D006801:Humans; D049410:Luciferases, Renilla; D008164:Luminescent Proteins; D011485:Protein Binding; D051381:Rats; D011949:Receptors, Cholecystokinin / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D012844:Sincalide / Q000031:analogs & derivatives / Q000378:metabolism; D013997:Time Factors; D014162:Transfection
chemical_list: C090019:8-sulfocholecystokinin octapeptide; D008164:Luminescent Proteins; D011949:Receptors, Cholecystokinin; D011993:Recombinant Fusion Proteins; C038823:cholecystokinin 58; D002766:Cholecystokinin; D049410:Luciferases, Renilla; D012844:Sincalide
references.citation: J Biol Chem. 1987 Jan 5;262(1):214-7
references.pmid: 3793725
references.citation: Am J Physiol. 1987 Oct;253(4 Pt 1):G477-82
references.pmid: 3661709
references.citation: Am J Physiol. 1999 Feb;276(2):R429-34
references.pmid: 9950921
references.citation: Pharmacol Toxicol. 2002 Dec;91(6):282-5
references.pmid: 12688369
references.citation: Pancreas. 2002 Oct;25(3):e50-5
references.pmid: 12370550
references.citation: Biochem Biophys Res Commun. 1999 Dec 20;266(2):400-4
references.pmid: 10600515
references.citation: Biochem Biophys Res Commun. 2002 May 10;293(3):1014-20
references.pmid: 12051761
references.citation: Am J Physiol Regul Integr Comp Physiol. 2007 Mar;292(3):R1071-80
references.pmid: 17082351
references.citation: Gastroenterology. 2008 Aug;135(2):632-41
references.pmid: 18555802
references.citation: Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G326-33
references.pmid: 15064233
references.citation: Am J Physiol Gastrointest Liver Physiol. 2004 Mar;286(3):G395-402
references.pmid: 14604858
references.citation: Am J Physiol. 1986 Mar;250(3 Pt 1):G344-9
references.pmid: 3953818
references.citation: Pancreas. 1996 Aug;13(2):130-9
references.pmid: 8829180
references.citation: J Cell Biol. 1995 Mar;128(6):1029-41
references.pmid: 7896869
references.citation: Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G866-79
references.pmid: 15550556
references.citation: Annu Rev Pharmacol Toxicol. 2002;42:409-35
references.pmid: 11807178
references.citation: J Comp Physiol Psychol. 1973 Sep;84(3):488-95
references.pmid: 4745816
references.citation: Biochemistry. 2007 Apr 17;46(15):4522-31
references.pmid: 17381074
references.citation: J Biol Chem. 2001 Dec 21;276(51):48040-7
references.pmid: 11673456
references.citation: Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G255-65
references.pmid: 12686511
references.citation: Mol Pharmacol. 1999 May;55(5):795-803
references.pmid: 10220557
references.citation: Biochemistry. 2006 Dec 12;45(49):14706-16
references.pmid: 17144663
references.citation: Am J Physiol Regul Integr Comp Physiol. 2005 Aug;289(2):R456-R462
references.pmid: 15831770
references.citation: J Biol Chem. 2007 Oct 19;282(42):30363-72
references.pmid: 17726027
references.citation: J Biol Chem. 2003 Dec 26;278(52):52972-9
references.pmid: 14534299
references.citation: Gastroenterology. 1993 Dec;105(6):1732-6
references.pmid: 8253350